Is SOLIGENIX, INC. (SNGX) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 12.4% / 30% | 65.1% / 30% | 0.0% / 30% | N/A | ✗ NOT HALAL |
| DJIM | 12.4% / 33% | 65.1% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| MSCI | 16.6% / 33% | 87.2% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| S&P | 12.4% / 33% | 65.1% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| FTSE | 16.6% / 33% | 87.2% / 33% | 0.0% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -165.1% | |
| Return on Assets (ROA) | -69.4% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$8M |
| Free Cash Flow | -$8M |
| Total Debt | $1M |
| Debt-to-Equity | 5.1 |
| Current Ratio | 3.2 |
| Total Assets | $9M |
Price & Trading
| Last Close | $1.21 |
| 50-Day MA | $1.21 |
| 200-Day MA | $1.68 |
| Avg Volume | 172K |
| Beta | 2.0 |
|
52-Week Range
$1.00
| |
About SOLIGENIX, INC. (SNGX)
Soligenix, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of products to treat rare diseases in the United States. It operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a photodynamic therapy, which has completed Phase 3 clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator (IDR) technology that is in Phase 3 clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX945, an IDR technology that is in Phase 2a study to treat aphthous ulcers in Behçet's disease; and SGX302, an IDR technology, which is in Phase 2a study for the treatment of mild-to-moderate psoriasis. Its Public Health Solutions segment engages in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase 1a, 1b, and 1c clinical trials; SGX943, a therapeutic candidate in preclinical studies for the treatment of antibiotic-resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; CiVax, a vaccine candidate for the prevention of COVID-19; and vaccine programs that target filoviruses, such as Marburg and Ebola. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in September 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is SOLIGENIX, INC. (SNGX) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), SOLIGENIX, INC. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is SOLIGENIX, INC.'s debt ratio?
SOLIGENIX, INC.'s debt ratio is 12.4% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 16.6%.
What are SOLIGENIX, INC.'s key financial metrics?
SOLIGENIX, INC. has a market capitalization of $11M. Return on equity stands at -165.1%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.